Cargando…
Espindolol for the treatment and prevention of cachexia in patients with stage III/IV non‐small cell lung cancer or colorectal cancer: a randomized, double‐blind, placebo‐controlled, international multicentre phase II study (the ACT‐ONE trial)
BACKGROUND: Cancer cachexia is a major cause of morbidity and mortality with no widely approved treatment. METHODS: The ACT‐ONE trial is a randomized, double‐blind, parallel group, placebo‐controlled, phase II multicentre trial in patients (25‐80 years) with stages III or IV colorectal cancer or non...
Autores principales: | Stewart Coats, Andrew J., Ho, Gwo Fuang, Prabhash, Kumar, von Haehling, Stephan, Tilson, Julia, Brown, Richard, Beadle, John, Anker, Stefan D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4929828/ https://www.ncbi.nlm.nih.gov/pubmed/27386169 http://dx.doi.org/10.1002/jcsm.12126 |
Ejemplares similares
-
The anabolic catabolic transforming agent (ACTA) espindolol increases muscle mass and decreases fat mass in old rats
por: Pötsch, Mareike S., et al.
Publicado: (2013) -
The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: study design
por: Stewart Coats, Andrew J., et al.
Publicado: (2011) -
The Journal of Cachexia, Sarcopenia and Muscle stays the front‐runner in geriatrics and gerontology
por: Anker, Markus S., et al.
Publicado: (2019) -
The 10th year of the Journal of Cachexia, Sarcopenia and Muscle
por: Anker, Markus S., et al.
Publicado: (2020) -
Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2021
por: von Haehling, Stephan, et al.
Publicado: (2021)